A certificate of analysis, often abbreviated COA, can look authoritative while leaving its connection to a product unclear. Begin with identity: what material does the document name, which lot does it describe and how is it connected to the preparation being proposed?
The HHS interim policy's KPV appendix identifies KPV acetate and includes characterization requirements for bulk material. That context makes the chemical form and lot-specific documentation relevant. A generic page saying “KPV tested” omits information needed to understand the match.
Read the header before the purity number
- Complete material name and stated chemical form.
- Manufacturer or supplier information shown.
- Lot or batch identifier.
- Sample and report dates.
- Tests, methods and results actually reported.
- Connection between that material and the dispensed preparation.
Do not silently treat free-base and acetate descriptions as identical paperwork. Ask the pharmacist or responsible professional to explain any difference between the prescription, ingredient document and finished-product label. Preserving exact names is more useful than guessing from an abbreviation.
A high percentage answers a limited question
Ask what a quoted purity value measures and what it excludes. The number should not be used as a shorthand for every quality characteristic, suitability for every route or proof of benefit. Those are separate questions with different evidence requirements.
Also distinguish the starting material from the finished preparation. A report describing a bulk ingredient does not automatically document every step involved in preparing and supplying the actual medication. Ask how that connection is maintained.
You do not need to act as the laboratory
The patient-facing goal is traceability and an accountable explanation. Request a plain-language response about the relevant documentation and who can resolve questions. An attractive report should not require you to independently certify analytical methods to make sense of the proposal.
Keep the document with the product description and the date of the discussion. If the product changes, revisit the match rather than assuming that old paperwork describes the new supply.
A useful COA discussion ends with a clear answer about identity, lot and scope. Clinical effectiveness still requires evidence about the relevant formulation and outcome, even when the quality paperwork is detailed.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.